Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.

Submission of Matters to a Vote of Security
Holders.

At our Annual Meeting of stockholders held on May25, 2017, our
stockholders voted on four matters as follows:

1. The following seven nominees were elected to our Board of
Directors to serve for a one-year term expiring at the 2018
annual meeting of stockholders:
Votes For Votes Against Votes Abstaining Broker Non-Votes

Jeffrey Berkowitz, J.D.

32,849,653 795,142 27,276 10,160,694

Anthony B. Evnin, Ph.D.

32,817,536 840,259 14,276 10,160,694

Michael G. Kauffman, M.D., Ph.D.

32,532,279 1,127,316 12,476 10,160,694

Adelene Q. Perkins

32,782,969 727,429 161,673 10,160,694

Norman C. Selby

32,791,412 799,453 81,206 10,160,694

Ian F. Smith

33,038,856 619,120 14,095 10,160,694

Michael C. Venuti, Ph.D.

32,790,768 852,008 29,295 10,160,694
2. A non-binding, advisory proposal on the compensation of the
Companys named executive officers was approved.

Votes For

VotesAgainst

VotesAbstaining

Broker Non-Votes

24,174,001

9,462,624 35,446 10,160,694
3. The shareholders recommended, in a non-binding, advisory
vote, that future advisory votes on the compensation of the
Companys named executive officers be held every three years.

Every3Years

Every2Years

Every1Year

Abstain

694,620

119,701 32,760,228 97,522

In light of the foregoing vote and consistent with the prior
recommendation of the Board of Directors, the Company intends to
hold future non-binding advisory votes on executive compensation
on an annual basis until the next required advisory vote on the
frequency of stockholder votes on executive compensation.

4. The appointment of Ernst Young LLP as our independent
registered public accounting firm for the current fiscal year
was ratified.

VotesFor

VotesAgainst

VotesAbstaining

BrokerNon-Votes

43,506,300

188,343 138,122


About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Recent Trading Information

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) closed its last trading session down -0.07 at 1.74 with 276,225 shares trading hands.